Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
60.1M
-
Shares change
-
+1.91M
-
Total reported value, excl. options
-
$2.67B
-
Value change
-
+$85.6M
-
Put/Call ratio
-
0.92
-
Number of buys
-
90
-
Number of sells
-
-67
-
Price
-
$44.43
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2020
197 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2020.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.1M shares
of 96M outstanding shares and own 62.63% of the company stock.
Largest 10 shareholders include Capital Research Global Investors (6.57M shares), Capital International Investors (6.13M shares), VANGUARD GROUP INC (4.97M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.71M shares), BlackRock Inc. (4.56M shares), FEDERATED HERMES, INC. (4.02M shares), Capital World Investors (3.24M shares), STATE STREET CORP (2.23M shares), FMR LLC (1.78M shares), and CITADEL ADVISORS LLC (1.63M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.